Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Albuterol Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Albuterol Tablets Prior Authorization

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs UnitedHealthcare prior authorization and medical-necessity coverage for albuterol tablets in adults and children age 6 years and older with obstructive airway disease.

    Policy Summary
    PayerUnitedHealthcare
    PolicyAlbuterol Tablets Prior Authorization
    Policy CodePolicy N/A
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, qualifying controller therapy, inhaled short-acting beta-agonist failure or intolerance, and prescriber risk-benefit attestation for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The July 2026 annual review updated the policy references.

    Age 6+Minimum age described in the indication
    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    1 controllerQualifying controller medications or regimens required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Positive response
    Required for reauthorization

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of obstructive airway disease (e.g., asthma).
    • The patient's obstructive airway disease is being managed with BOTH of the following:

      • ONE of the following controller medications:

        • An inhaled corticosteroid (e.g., Arnuity Ellipta, QVAR RediHaler).
        • An inhaled corticosteroid/long-acting beta-agonist (e.g., fluticasone/salmeterol [generic Advair Diskus], Advair HFA, Breo Ellipta, Symbicort).
        • Spiriva HandiHaler/Respimat.
        • A long-acting muscarinic antagonist/long-acting beta-agonist (e.g., Anoro Ellipta, Bevespi Aerosphere).
      • History of failure, contraindication, or intolerance to an inhaled short-acting beta-agonist (e.g., albuterol HFA [generic ProAir HFA, generic Proventil HFA, generic Ventolin HFA]).
    • Prescriber attests that the benefits outweigh the risk.
    Authorization will be issued for 12 months.

    State mandates may apply. Federal regulatory requirements, the member-specific benefit plan, and other policies or utilization management programs may also impact coverage.

    Continuation Therapy

    Covered when the following criterion is met:

    ALL of the following

    • Documentation of positive clinical response to therapy.
    • Authorization will be issued for 12 months.

      State mandates may apply. Federal regulatory requirements, the member-specific benefit plan, and other policies or utilization management programs may also impact coverage.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization and medical-necessity review are required for initial coverage of albuterol tablets. Approval requires meeting all initial authorization criteria, including the diagnosis, qualifying management regimen, inhaled short-acting beta-agonist history, and prescriber attestation that benefits outweigh risks.

    • Initial authorization is issued for 12 months when all criteria are met.
    Prior Authorization

    Reauthorization Requires Positive Response

    Reauthorization requires documentation that the patient has had a positive clinical response to albuterol tablet therapy. When this requirement is met, reauthorization is issued for 12 months.

    • Reauthorization duration: 12 months.

    Clinical Background

    Albuterol tablets are indicated for relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease. Guidelines do not recommend albuterol tablets because of their higher risk of side effects; long-term safety studies assessing the risk of severe exacerbations in patients not also taking an inhaled corticosteroid have not been performed.

    Albuterol Tablet Initial Authorization

    Albuterol Tablet Initial Authorization

    Initial authorization is approved when ALL of the following are met:

    Initial albuterol tablet therapy

    • Diagnosis of obstructive airway disease (e.g., asthma).
    • Current disease management

      • 1 medication or regimen

        Options include an inhaled corticosteroid; an inhaled corticosteroid/long-acting beta-agonist combination; Spiriva HandiHaler or Respimat; or a long-acting muscarinic antagonist/long-acting beta-agonist combination.

      • Inhaled short-acting beta-agonist history: History of failure, contraindication, or intolerance to an inhaled short-acting beta-agonist, such as albuterol HFA products.

    Albuterol Tablet Reauthorization

    Albuterol Tablet Reauthorization

    Reauthorization is approved when the following criterion is met:

    Positive clinical response: Documentation of a positive clinical response to albuterol tablet therapy.

    Authorization is issued for 12 months.

    Required Prior Therapy

    StepRequirement before albuterol tablet coverageFailure or exception requirement
    1Use or management with ONE qualifying controller medication or regimen: an inhaled corticosteroid; an inhaled corticosteroid/long-acting beta-agonist combination; Spiriva HandiHaler or Respimat; or a long-acting muscarinic antagonist/long-acting beta-agonist combination.History of failure, contraindication, or intolerance to an inhaled short-acting beta-agonist, such as albuterol HFA.
    Policy Summary
    PayerUnitedHealthcare
    PolicyAlbuterol Tablets Prior Authorization
    Policy CodePolicy N/A
    Change TypeAdministrative/reference update
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, qualifying controller therapy, inhaled short-acting beta-agonist failure or intolerance, and prescriber risk-benefit attestation for initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsClinical BackgroundAlbuterol Tablet Initial AuthorizationAlbuterol Tablet ReauthorizationRequired Prior Therapy
    Step Therapy

    Required Controller Therapy and Inhaled SABA History

    The obstructive airway disease must be managed with a qualifying controller medication and the patient must have a history of failure, contraindication, or intolerance to an inhaled short-acting beta-agonist.

    • Qualifying controller therapy includes an inhaled corticosteroid; an inhaled corticosteroid/long-acting beta-agonist combination; Spiriva HandiHaler or Respimat; or a long-acting muscarinic antagonist/long-acting beta-agonist combination.
    • Document failure, contraindication, or intolerance to an inhaled short-acting beta-agonist, such as albuterol HFA products.
    Documentation Required

    Initial Authorization Documentation

    For initial authorization, submit documentation of obstructive airway disease, the qualifying controller medication or regimen, and the history of failure, contraindication, or intolerance to an inhaled short-acting beta-agonist. The prescriber must also attest that the benefits of albuterol tablets outweigh the risks.

    • Diagnosis example: asthma or other obstructive airway disease.
    • Include the controller therapy or regimen and the relevant inhaled short-acting beta-agonist history.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, document that the patient has experienced a positive clinical response to albuterol tablet therapy.

    • Positive clinical response documentation is required for continued coverage.
    • Reauthorization is issued for 12 months when the response requirement is satisfied.
    Denial Risk

    Initial Criteria Not Met

    Initial coverage may be denied when any required medical-necessity criterion is not satisfied. This includes lack of a qualifying diagnosis, controller therapy, required inhaled short-acting beta-agonist history, or the prescriber’s benefits-versus-risks attestation.

    • All initial authorization criteria must be met.
    Denial Risk

    No Positive Clinical Response

    Reauthorization is at risk of denial when the record does not document a positive clinical response to albuterol tablet therapy.

    • Document the patient’s positive response before requesting reauthorization.
  1. Risk-benefit attestation: The prescriber attests that the benefits outweigh the risk.